Free shipping on all orders over $ 500

LJI308

Cat. No. M7566

All AbMole products are for research use only, cannot be used for human consumption.

LJI308 Structure
Size Price Availability Quantity
5mg USD 180  USD180 In stock
10mg USD 300  USD300 In stock
25mg USD 660  USD660 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LJI308 efficiently inhibits RSK activity. LJI308 inhibites S6K1 with an IC50 of 0.8 μM, representing a 200-fold lower inhibition than that of RSK2. LJI308 inhibits MEK4 less than 50% at 10 μMand HIP kinase 1 less than 50% at 1 μM. LJI308 inhibits the growth and survival of TNBC. LJI308 also suppresses the growth of HTRY-LT cells in 3-dimensional soft agar cultures. LJI308 is one of the first potent and effective targeted therapies for TNBC that, unlike currently utilized drugs, exhibits efficacy in eliminating the CSC population.

Protocol (for reference only)
Cell Experiment
Cell lines HTRZ and HTRY-LT1 cell lines
Preparation method Viability of HTRZ and HTRY-LT1 cell lines treated with increasing doses of LJI308 (1 - 10 μM) for 96 hours. DMSO treated cells served as a control.
Concentrations 1 - 10 μM
Incubation time 96 h
Animal Experiment
Animal models
Formulation
Dosages
Administration
Chemical Information
Molecular Weight 368.38
Formula C21H18F2N2O2
CAS Number 1627709-94-7
Form Solid
Solubility (25°C) 32 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Davies AH, et al. Oncotarget. Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells.

[2] Aronchik I, et al. Mol Cancer Res. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers.

Related S6 Kinase Products
BI-D1870

BI-D1870 is an ATP-competitive, cell permeable and brain penetrated inhibitor of the p90 RSK (ribosomal S6 kinase) with IC50 values of 31 nM, 24 nM, 18 nM, 15 nM for RSK1, RSK2, RSK3, RSK4, respectively.

PF-4708671

PF-4708671 is a novel cell-permeable inhibitor of S6K1 with Ki/IC50 value of 20 nM/160 nM. PF4708671 inhibits MSK1 (IC50 of 0.95 μM) 4-fold more weakly than S6K1.

FMK

FMK is a potent and selective inhibitor of p90 ribosomal protein S6 kinaseRSK2 (wt) with IC50 of 15 nM, >600- and 200-fold selectivity for RSK2 than the C436V and T493M mutants.

SL 0101-1

SL-0101-1 is a selective p90 RSK inhibitor for RSK2 with IC50 of 89 nM.

Quercitrin

Quercitrin (Quercitrin) is a natural compound in bitter buckwheat, which has anti-inflammatory effects and has the potential to be used in cardiovascular disease research.

  Catalog
Abmole Inhibitor Catalog




Keywords: LJI308 supplier, S6 Kinase, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.